Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma

Sorrento Therapeutics, Inc. (SRNE) 
Last sorrento therapeutics, inc. earnings: 8/9 04:49 pm Check Earnings Report
US:NASDAQ Investor Relations: sorrentotherapeutics.com/investors
Company Research Source: GlobeNewswire
SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an innovative immunotherapy company, announced today that the first patients were dosed in a Phase 1 study to evaluate the safety and efficacy of CD38 CAR-T therapy in relapsed or refractory multiple myeloma patients at two clinical sites – University of Pennsylvania (UPenn) in Philadelphia and Roger Williams Medical Center in Rhode Island. The CD38 CAR-T cells manufactured at both Sorrento cGMP facilities (San Diego, CA and Providence, RI) met all release specifications and were used in the study. This study is the first US-based clinical trial targeting CD38 using an autologous CAR-T cell therapy. Details on the study can be found at: www.clinicaltrials.gov : NCT03464916. Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma. About Sorrento Therapeut Show less Read more
Impact Snapshot
Event Time:
SRNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for SRNE alerts
Opt-in for
SRNE alerts

from News Quantified
Opt-in for
SRNE alerts

from News Quantified